A new functional parameter measured at the time ablation that can be used to predict differentiated thyroid cancer recurrence during follow-up

European Journal of Endocrinology

Volumn 156, Issue 1, 2007, Pages 41-47

  Verkooijen, Robbert B T ^a   Rietbergen, Daphne ^a   Smith, Jan W ^a   Romijin, Johannes A ^a   Stokkel, Marcel P M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROTROPIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADULT; AGE DETERMINATION; ARTICLE; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL RATE; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME; BLOOD; MIDDLE AGED; PREDICTION AND FORECASTING; STIMULATION; THYROID TUMOR; TUMOR RECURRENCE;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STIMULATION, CHEMICAL; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN;

EID: 33847732278     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02322     Document Type: Article

References (27)

1. Utiger RD. Follow-up of patients with thyroid carinoma. New England Journal of Medicine 1997 44 493-495.
2. Stojadinovic A, Shoup M, Nissan A, Ghossein RA, Shah JP, Brennan MF & Shaba AR. Recurrent differentiated thyroid carcinoma: biological implications of age, method of detection, and site and extent of recurrence. Annals of Surgical Oncology 2002 9 789-798.
3. Verkooijen RBT, Stokkel MPM, Smit JWA & Pauwels EKJ. Radio-iodine-131 in differentiated thyroid cancer: arctrospective analysis of an uptake-related ablation strategy. European Journal of Nuclear Medicine and Molecular Imaging 2004 31 499-506.
4. Maxon HR III, Englaro, EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D & Aden MD. Radioiodine-131 therapy for well-differentiated thyroid cancer - a quantifive radiation dosimetric approach: outcome and validation in 85 patients. Journal of Nuclear Medicine 1992 33 1132-1136.
5. 131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology 2005 15 3 651-659.
6. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW & Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787-803.
7. Dam HQ, Kim SM, Lin HC & Intenzo CM. I-131 therapeutic efficacy is not influenced by stunning after diagnostic whole-body sanning. Radiology 2004 232 527-533.
8. Lassmann M, Luster M, Hanscheid H & Reiners C. Impact of I-131 diagnostic activities on the biokinetics of thyroid remnants. Journal of Nuclear Medicine 2004 45 619-625.
9. Kalinyak JE & McDougall IR. Whole-body scanning with radionuclides of iodine, and the controversy of thyroid stunning. Nuclear Medicine Communications 2004 25 883-889.
10. Jukkola A, Bloigu R, Ebeling T, Salmela P & Blanco G. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocrine-Related Cancer 2004 11 571-579.
11. Giovanella L, Ceriani L, Bhelfo A & Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clinical Chemistry and Laboratory Medicine 2005 43 843-847.
12. Lo CY, Chan WF, Lam KY & Wan KY. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Annals of Surgery 2005 242 707-715.
13. Falvo L, Catania A, Sorrenti S, D'andrea V, Berni A, De Stefano M & De Antoni E. Prognostic significance of the age factor in the thyroid cancer: statistical analysis. Journal of Surgical Oncology 2004 88 217-222.
14. Haigh PI, Urbach DR & Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Annals of Surgical Oncology 2005 12 81-89.
15. Cushing SL, Palme CE, Audet N, Eski S, Walfish PG & Freeman JL. Prognostic factors in well-differentiated thyroid carcinoma. Laryngoscope 2004 114 2110-2115.
16. Borson-Chazot F, Causeret S, Lifante J, Augros M, Berger N & Peix J. Predictive factors for recurrence from a series of 74 children and adolescents with differentiated thyroid cancer. World Journal of Surgery 2004 28 1088-1092.
17. Haq M & Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clinical Endocrinology 2005 63 87-93.
18. Rodriquez-Cuevas S, Labastida-Almendaro S, Cortes-Arroyo H, Lopez-Garza J & Barroso-Bravo S. Multifactorial analysis of survival and recurrences in differentiated thyroid cancer. Journal of Experimental and Clinical Cancer Research 2002 21 79-86.
19. Volante M, Cavallo GP & Papotti M. Prognostic factors of clinical interest in poorly differentiated carcinomas of the thyroid. Endocrine Pathology 2004 15 313-317.
20. Süronen P. Louhimo J, Nordling S, Ristimaki A, Maenpaa H. Haapiainen R & Haglund C. Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumor Biology 2005 26 57-64.
21. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, Caillou B, Travagli JP & Schlumberger M. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002 12 707-711.
22. Bernier MO, Morel O, Rodien P, Muratet JP, Giraud P, Rohmer V, Jeanguillaume C, Bigorgne JC & Jallet P. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2005 32 1418-1421.
23. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, Travagli JP & Schlumberger M. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. Journal of Clinical Endocrinology and Metabolism 2005 90 5723-5729.
24. Hall FT, Beasly NJ, Eski SJ, Witterick IJ, Walfish PG & Freeman JL. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope 2003 113 77-81.
25. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP & Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism 2003 88 1107-1111.
26. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, Riedinger JM, Boichot C, Cochet A & Brunotte F. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (I-131) ablation therapy in patients with differentiated thyroid cancer. Journal of Nuclear Medicine 2004 45 988-994.
27. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ & Shong YK. Serum thyroglobulin levels at the time of I-131 remnant ablation just after thyroldectorny are useful of early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2005 90 1440-1445.